Effect of resveratrol on the development of spontaneous mammary tumors in HER‐2/neu transgenic mice
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Resveratrol (Res) has been reported to possess cancer chemopreventive activity on the basis of its in vitro effects on tumor cells and in vivo experimental models of rodents transplanted with parental tumors or treated with carcinogens. We investigated the effects of Res on the development of mammary tumors appearing spontaneously in HER‐2/neu transgenic mice at an early age. The mechanisms involved in the Res antitumor effect were evaluated by studying the immune effectiveness, tumor apoptosis and expression of mRNA and protein for HER‐2/neu in tumoral mammary glands from Res‐treated mice and in tumor cell lines. Res supplementation delayed the development of spontaneous mammary tumors (p < 0.001), reduced the mean number and size of mammary tumors (p < 0.0001) and diminished the number of lung metastases in HER‐2/neu transgenic mice. The effects of Res were associated with downregulation of HER‐2/neu gene expression and increased apoptosis both in tumoral mammary glands and in murine (N202) and human (SKBr3) tumor cell lines. Neither the basal, the IL‐2‐induced NK activity nor the lymphocyte number and proliferation was modified in Res‐supplemented compared to control mice. Our results demonstrate that Res supplementation delays the development and reduces the metastasizing capacity of spontaneous mammary tumors in HER‐2/neu transgenic mice. The antitumor effect of Res might be related to the downregulation of HER‐2/neu expression and the induction of apoptosis in tumor cells. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · cited 4×
“1,8–12 Jang et al.(1) reported FIGURE 3 – Effect of Res supplementation on HER-2/neu mRNA expression in tumoral mammary glands.”
BackgroundInfluential
Cited by
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
The Role of Resveratrol in Cancer Therapy
Ko, J.-H., Sethi, G., Um, J.-Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., Bishayee, A., & Ahn, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122589 · Cited by 800
Resveratrol: A review of preclinical studies for human cancer prevention
ATHAR, M., BACK, J., TANG, X., KIM, K., KOPELOVICH, L., BICKERS, D., & KIM, A. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.025 · Cited by 731
Cancer Prevention and Treatment with Resveratrol: From Rodent Studies to Clinical Trials
Bishayee, A. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0160 · Cited by 528
Resveratrol and cancer: focus on in vivo evidence
Carter, L. G., D'Orazio, J. A., & Pearson, K. J. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0171 · Cited by 522
Metadata
- Authors
- Provinciali, M., Re, F., Donnini, A., Orlando, F., Bartozzi, B., Di Stasio, G., & Smorlesi, A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2005-02
- Volume
- 115
- Issue
- 1
- Pages
- 36-45
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2016501204
- Cited by
- 123
- References
- 1
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.